Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 August 2021 | Story Nonsindiso Qwabe | Photo Sonia Small (Kaleidoscope Studios)
New member of the Pontifical Academy of Social Sciences - Prof Pearl Sithole

Social scientist and Vice-Principal: Academic and Research on the Qwaqwa Campus, Prof Pearl Sithole, was appointed by Pope Francis as a member of the Pontifical Academy of Social Sciences for her stellar work in social sciences. 
Academicians are appointed by the Pope on the basis of their competencies in the social sciences and their moral integrity.

Prof Sithole said she was looking forward to sharing meaning and impact with the world through a space dedicated to the social sciences. “It’s a great honour. I’m feeling really humbled. The social sciences and humanities are a hugely necessary space to make meaning of the world, but for some reason, in the pecking order, they were relegated to a space that is thought of last. This appointment is to a dedicated space – to say, let’s look at issues through that lens.”
The Pontifical Academy of Social Sciences was established by Pope John Paul II in 1994 with the aim of promoting the study and progress of the social sciences, primarily economics, sociology, law, and political science. To achieve its aims, the academy organises conferences and workshops on specific themes, promotes scientific surveys and research, and publishes publications. 

Prof Sithole said the academy provides a wonderful way of reminding academicians of the importance of relating science to the real world. 

“What I like about it is that it demystifies science. It says, be excellent in your field but be able to converse for impact, be able to come to a forum that worries about specific issues, it still encourages publications and pure science/scientific endeavours, advancements in their field, but sometimes people come together to look at an issue from various angles. For me, it’s such a wonderful way of saying we must remember that we are doing science in order to relate to the world, not just to understand for the sake of understanding,” she said.

Make a genuine effort to make a difference in whatever you do, and your work will speak for itself.- Prof Pearl Sithole. 

The appointment also coincides with Women’s Month, and Prof Sithole said she takes great pride in her womanhood. 

“I am a mother and a daughter. I strive to pinpoint problems and offer solutions. I am a social scientist. I’ve made it a mission to study how systems affect people by infusing humanity within the systems. Women have been made to be apologetic about the qualities that define us as women, which we bring especially into leadership. I don’t apologise for my emotions. I don’t apologise for my multitasking abilities; however, I do feel that women are often abused for having these.”

What would you say makes you a UFS woman of quality, impact, and care?

I am the sort of person who strongly believes that your work should speak for itself. I don’t work for accolades. My approach to life is to work genuinely to make a difference, and your work will speak for itself. If you wake up every day to genuinely make a difference, it is enough. You get a lot of satisfaction in life, and you sleep better because you know you have given it your best, and you know that sometimes you can actually see it making a difference.

What advice would you give to the 15-year-old you?

I would say, be true to yourself. At a younger age, you want to chase all sorts of aspirations that look glamorous, which is not a bad thing, because you have to have appetite; but in your appetite for excellence and as someone who lives for a purpose, be true to yourself. Be able to design a life that aspires, but at the same time be adaptable to what you discover your strengths to be.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept